ArticleIrish journal of medical science2025
Exploring the impact of IKZF1 and its targeting microRNAs in the pathogenesis of acute lymphoblastic leukemia.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy driven by uncontrolled immature lymphoid cell proliferation. Its prognosis is significantly influenced by IKZF1 gene alterations which contribute to treatment resistance and relapse.
aimThis study investigates the role of specific IKZF1-targeting microRNAs (e.g., hsa-miR-488, hsa-miR-4311) in ALL pathogenesis and their potential as therapeutic targets.
methodsPeripheral blood samples were collected from 32 ALL patients and 20 healthy controls. Total RNA and miRNAs were extracted, and cDNA was synthesized. Quantitative real-time PCR was performed to evaluate the expression of IKZF1 and the candidate miRNAs. Statistical analyses included non-parametric tests to compare expression levels between groups.
resultsIKZF1 expression was significantly reduced in ALL patients compared to controls (median: 0.1160 vs. 0.8245; p = 0.002). Among the miRNAs analyzed, only hsa-miR-8085 showed a significant decrease in ALL patients (median: 0.0192 vs. 0.3411; p = 0.008). No significant differences were observed for hsa-miR-488, hsa-miR-4311, hsa-miR-6731-5p, or hsa-miR-6833-3p.
conclusionsThe significant downregulation of IKZF1 and hsa-miR-8085 in ALL patients suggests their involvement in the development of leukemia and highlights their potential as diagnostic markers or therapeutic targets.
Indexed as
Identifiers
40779139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.